Replies to post #225603 on Biotech Values

[dewophile]

A single arm study with adequate efficacy is definitely enough - my point is that the data being presented are unlikely to be mature enough (and probably not robust enough given the size of the trial) to be sufficient to support approval "sooner than later"
If data are promising I would think they need to expand the trial and open up some additional sites to enable an accelerated filing